COURAGE to be conservative Megan CoylewrightRoger S. BlumenthalWendy Post Invited Commentary 01 February 2008 Pages: 1 - 2
Folic acid, homocysteine, and cardiovascular disease: Are the dots connecting? José M. Ordovas Clinical Trials Report 01 February 2008 Pages: 7 - 8
Nutrition, lipids, and cardiovascular disease: Clinical benefits without biochemical effects and biochemical effects without clinical benefits Lewis H. Kuller OriginalPaper 01 February 2008 Pages: 9 - 14
The other lipids: Ectopic lipids with emphasis on skeletal muscle Lan Chi T. LuuEric Ravussin OriginalPaper 01 February 2008 Pages: 15 - 22
Lipoprotein subclasses—A changing landscape Michael Y. TsaiJing Cao OriginalPaper 01 February 2008 Pages: 23 - 28
Using inflammatory biomarkers to guide lipid therapy Brendan M. EverettPaul M. Ridker OriginalPaper 01 February 2008 Pages: 29 - 34
Raising HDL cholesterol for cardiovascular disease prevention: Is this still feasible? Guido FranceschiniLaura Calabresi OriginalPaper 01 February 2008 Pages: 35 - 40
Glycated proteins and cardiovascular disease in glucose intolerance and type 2 diabetes Robert S. RosensonWilliam H. Herman OriginalPaper 01 February 2008 Pages: 43 - 46
Obesity and cardiovascular disease risk in children and adolescents Sara M. ParisiElizabeth Goodman OriginalPaper 01 February 2008 Pages: 47 - 52
Inflammation, insulin resistance, and cardiovascular disease: Cause or correlate? Naveed Sattar OriginalPaper 01 February 2008 Pages: 53 - 59
Associations of insulin resistance and type 2 diabetes to heart failure: Epidemiology, potential mechanisms, and clinical perspectives Erik Ingelsson OriginalPaper 01 February 2008 Pages: 60 - 65
Glycemic control to prevent cardiovascular disease in type 2 diabetes Amanda Adler OriginalPaper 01 February 2008 Pages: 66 - 71
The endocannabinoid system, Obesity, and insulin resistance Stefan Engeli OriginalPaper 01 February 2008 Pages: 72 - 78